iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Dr Reddy’s recalls 4,000 units of Tacrolimus in US due to faulty packaging

8 Mar 2023 , 12:45 PM

Dr Reddy’s Laboratories informed that the company is recalling over 4,000 bottles of a generic drug in the United States.

The Hyderabad-based pharmaceutical company is recalling 4,320 bottles of Tacrolimus Capsules, which are used to prevent the body from rejecting an organ transplant. The pharma major is recalling bottles due to a packaging defect.

Dr Reddy’s Laboratories Inc, based in New Jersey, is recalling the affected lot due to the ‘presence of one Tacrolimus 1 mg capsule co-mingled in a bottle containing and labelled as Tacrolimus 0.5 mg capsules,’ according to the USFDA’s latest Enforcement Report.

The affected lot was manufactured at the company’s Bachupally-based manufacturing plant and distributed in the United States by its American subsidiary.

On February 8, this year, Dr Reddy’s began a nationwide Class II recall.

At around 12.42 PM, Dr Reddy’s was trading 0.28% lower at Rs4,428 apiece, against the previous close of Rs4,439.20 on NSE. The counter touched an intraday high and low of Rs4,444 and Rs4,401.25 respectively.

For feedback and suggestions, write to us at editorial@iifl.com

explored-media

Related Tags

  • Class II Recall
  • Dr Reddy's Drug
  • Dr Reddy's drug recall
  • Dr Reddys
  • Dr Reddys Laboratories
  • Dr reddys news
  • Drug Recall
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.